This is an international, multicenter, open-label, non-comparative, Simon´s two-stage design,
phase II clinical trial.
To explore after 6 months of treatment the ability of palbociclib in combination with
letrozole to induce global molecular changes measured by either the Oncotype DX Breast
Recurrence Score® (the "Assay") test result at surgery (post-treatment Recurrence Score® (RS)
result), or pathological Complete Response (pCR) in patients with aggressive luminal tumors
(pre-treatment RS result 18-25 or 26-100, and Ki67≥ 20).
- To explore the ability of palbociclib in combination with letrozole to induce global
molecular changes measured by post-treatment RS result, in patients with aggressive
luminal tumors (pre-treatment RS result 18-25 and Ki67≥ 20) after 6 months of treatment.
- To explore the ability of palbociclib in combination with letrozole to induce global
molecular reduction measured by either the post-treatment RS result, and/or Residual
Cancer Burden (RCB), and/or Ki67 in patients with aggressive luminal tumors
(pre-treatment RS result 18-25 or 26-100 and Ki67 ≥ 20) after 6 months of treatment.
- To verify the ability of palbociclib in combination with letrozole to induce global
molecular reduction (measured as either post-treatment RS≤25 or RCB score of 0-I) in
>35% of patients in cohort B with pre-treatment RS 26-100;
- To verify the ability of palbociclib in combination with letrozole to induce increase in
RS result (measured as post-treatment RS 26-100) in <3% of patients in cohort A with
pre-treatment RS 18-25;
- To evaluate the concordance rate between the RCB score (0- I vs. II-III) and the
post-treatment RS result in both cohorts of patients after treatment with palbociclib in
combination with letrozole;
- To evaluate the concordance rate between the preoperative endocrine prognostic index
(PEPI) score and post-treatment RS result in both cohorts of patients after treatment
with palbociclib in combination with letrozole;
- To evaluate the concordance rate between the pCR and the post-treatment RS result in
both cohorts of patients after treatment with palbociclib in combination with letrozole;
- To determine the change in RS result as measured by median absolute value or median
percentage after 6 months of treatment: from pre-treatment RS 18-25 to post-treatment RS
0-17 for patients in cohort A and from pre-treatment RS 26-100 to post-treatment RS≤25
for patients in cohort B.
- To determine the Overall Response Rate (ORR) of patients treated with palbociclib in
combination with letrozole.
- To evaluate the Maximum Tumor Shrinkage of palbociclib in combination with letrozole.
- To determine the rate of breast conserving surgery.
• To assess the safety and tolerability of palbociclib in combination with letrozole.
A two-stage Simon's statistical design will be used for both cohorts (minimax design in
co-hort B and optimal design in cohort A). A total of 66 patients will be enrolled into this
trial, N=33 patients in cohort with high-risk tumors (Cohort B: pre-treatment RS>25) and N=33
patients in cohort with intermediate-risk tumors (Cohort A: pre-treatment RS18-25).
The accrual goal will be of 26 patients (N=13 patients in each cohort) during the first
stage. The interim analysis has been planned after 15 patients (cohort B) and 9 patients
(cohort A) will be available for biological response evaluation, and in case of positive
findings, the trial will recruit additional 40 patients (N=20 patients in each cohort).
- The study would be defined as positive at final analysis in the cohort B (pre-treatment
RS>25), if 8 or more than 8 patients with biological signal (post-treatment RS≤25) are
observed (≥28.6%) among 28 evaluable patients.
- The study would be defined as positive at final analysis in the cohort A (pre-treatment
RS18-25), if 25 or more than 25 patients with biological stabilization (post-treatment
RS≤25) are observed (≥89.3%) among 28 evaluable patients.
Study treatment management
After signing the informed consent form (ICF) and confirmed pre- eligibility, patients will
be pre-registered in the study. A tissue biopsy from the primary breast cancer has to be
provided at screening and will be used to perform central confirmation of Ki67 levels and HR
status, as well as central assessment of RS. Pre-registered patients can receive up to 4
weeks of letrozole before inclusion; pre-menopausal patients will require to combine it with
a Luteinizing Hormone-Releasing Hormone (LHRH) analogue. Patients are eligible to enter one
of the two cohorts according to RS assessment as follow:
- Cohort A: patients with pre-treatment RS 18-25;
- Cohort B: patients with pre-treatment RS 26-100. Patients with pre-treatment RS 0-17
will be considered not eligible. Patients allocated to the cohort A or B will receive 24
weeks of palbociclib (for 21 days every 4 weeks) in combination with letrozole (once
daily, beginning on day 1 and continuing through day 28 of every 28-day cycle).
Premenopausal women must also be treated with an LHRH analogue during the treatment
Patients must meet ALL of the following inclusion criteria to be eligible for enrolment
into the study:
1. Female patients over 18 years of age.
2. Patients have been informed about the nature of study, have agreed to participate in
the study, and have signed the informed consent form prior to participation in any
3. Premenopausal and postmenopausal women. Premenopausal women must be treated with LHRH
analogue since patient pre- registration. Premenopausal or postmenopausal status
should have been established before starting study treatment with letrozole plus
palbociclib based on the following classification:
1. Postmenopausal status is defined as either:
- Prior bilateral oophorectomy; Or
- Age>60 years; Or
- Age<60 years and amenorrhoeic for 12 months in the absence of chemotherapy,
tamoxifen, toremifene or ovarian suppression, and follicle-stimulating
hormone (FSH) and estradiol in postmenopausal range.
2. Premenopausal status is defined as all those women who do not meet any of above
4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
5. Histologically confirmed infiltrating breast cancer.
6. HR-positive (estrogen receptor [ER]-positive and/or progesterone receptor
[PgR]-positive) EBCs (breast cancers that have at least 10% of cells staging positive
for ER and/or PgR). ER and/or PgR status will be centrally confirmed by using
immunohistochemistry (IHC) testing for an Allred score of 6-8 in at least one of them.
7. Patients with HER2-negative breast cancer through in situ hybridization test
(fluorescence in situ hybridization [FISH], chromogenic in situ hybridization [CISH],
or silver enhanced in situ hybridization [SISH]) or negative immunohistochemical
status of 0, 1+, or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or
SISH) test is required.
8. Ki67 levels ≥ 20% confirmed by IHC testing in a central laboratory.
9. Tumor size > 2,0 cm (T2-4 according to TNM staging system, but always > 2,0 cm) by
mammogram, breast ultrasound, or breast magnetic resonance imaging (MRI).
10. Patients must have a measurable disease by mammogram and/or breast ultrasound.
11. Patients with two significant lesions (both larger than 1 cm and with more than 1 cm
distance between them) will require tumor sample from both lesions and proper
preoperative marking of both. To be registered, both lesions should fulfil inclusion
criteria 5 and 6 and both tumor samples will be submitted. Patient with more than 2
significant lesions will not be eligible.
12. Limited node involvement (N0-2, according to TNM staging system), assessed by
ultrasound. Sentinel lymph node biopsy or axillary dissection, are allowed.
13. No metastatic disease (M0, according to TNM staging system).
14. Available pre-treatment tissue sample (biopsy) material (formalin- fixed
paraffin-embedded (FFPE) for central confirmation and RS evaluation by the Assay.
15. Patients agree to collection of tissue biopsy from the primary breast cancer at the
time of study inclusion (screening), at Cycle 1 Day 14 of treatment, and after 24
weeks (surgery), or if experience intolerable side effects, disease progression, or
withdraw during 24 weeks of study treatment.
16. No prior chemotherapy, endocrine, or radiation therapy for current disease.
17. Adequate organ function:
1. Hematological: White blood cell (WBC) count ≥ 3.0 x 109/L, absolute neutrophil
count (ANC) ≥ 1.5x 109/L, platelet count ≥ 75.0 x109/L, and hemoglobin ≥ 10.0
g/dL (≥ 6.2 mmol/L).
2. Hepatic: Bilirubin ≤ 1.5 times the upper limit of normal (x ULN) (or total
bilirubin ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN in patients with
well-documented Gilbert's syndrome); alkaline phosphatase (ALP) ≤ 2.5 times ULN;
aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 times ULN.
3. Renal: Serum creatinine ≤ 1.5 x ULN.
18. Resolution of all acute toxic effects of prior surgical procedures to grade ≤1 as
determined by the NCI CTCAE v.5.0.
Patients will be excluded from the study if they meet ANY of the following criteria:
1. Metastatic progression (M1, according to TNM staging system).
2. Substantial nodal involvement (N>2, according to TNM staging system).
3. Non-large tumor (T0-1, according to TNM staging system).
4. Bilateral breast carcinoma.
5. Inflammatory carcinoma (T4d, according to TNM staging system).
6. Patient with multicentric or multifocal (more than 2 lesions) breast cancer.
7. Excisional biopsy of the primary tumor.
8. Known hypersensitivity to any palbociclib excipients.
9. Known hypersensitivity to any letrozole excipients.
10. Patients unable to swallow tablets.
11. Patients have a concurrent malignancy or malignancy within five years of study
enrollment with the exception of carcinoma in situ of the cervix, non-melanoma skin
carcinoma, or stage I uterine cancer. For other cancers considered to have a low risk
of recurrence, discussion with the Medical Monitor is required.
12. Previous radiotherapy on the ipsilateral chest wall for the treatment of any other
13. Major surgery (defined as requiring general anesthesia) or significant traumatic
injury within four weeks of start of study treatment, or patients who have not
recovered from the side effects of any major surgery, or patients that may require
major surgery during the course of the study.
14. Have a serious concomitant systemic disorder (i.e., active infection including HIV, or
cardiac disease) incompatible with the study (at the discretion of investigator).
15. Patients with an active bleeding diathesis, previous history of bleeding diathesis, or
anti-coagulation treatment (the use of low molecular weight heparin is allowed as soon
as it is used as prophylaxis intention).
16. History of malabsorption syndrome or other condition that would interfere with enteral
17. Chronic daily treatment with corticosteroids with a dose of ≥ 10mg/day
methylprednisolone equivalent (excluding inhaled steroids).
18. QTc interval > 480 msec on basal assessments, personal history of long or short QT
syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes
19. Uncontrolled electrolyte disorders that can compound the effects of a QTc-prolonging
drug (i.e., hypocalcemia, hypokalemia, or hypomagnesemia).
20. Participation in the treatment phase of an interventional trial within 30 days prior
to study treatment start.